We held a one hour session where Mark Roithmayr, CEO Alzheimer’s Drug Discovery Foundation (a pure Venture Philanthropy nonprofit), interviewed John Walter, CEO Food Allergy Science Initiative, who has helped... read more →
Building on past presentations where we spotlighted the individual efforts of the Leukemia & Lymphoma Society, Foundation Fighting Blindness, and JDRF, in another of our Venture Philanthropy series we heard... read more →
The Flinn Foundation launched the bioscience Entrepreneurship Program in 2014 to foster entrepreneurship and help bioscience founders/CEOs develop their early-stage companies into successful and sustainable businesses bringing new therapies, medical... read more →
In November 2016, HRA sponsored a workshop at the FDA entitled “Gene Editing: FDA-Regulated Technologies and Applications.” The keynote speaker was Jennifer Doudna and her talk was titled “CRISPR-Cas Genome... read more →
Venture philanthropy does not come without its fair share of controversy. It remains a challenge for nonprofits, philanthropists, patients, start-ups and the general public to determine how – and if... read more →
Institutional Review Boards (IRBs) play a hidden but critical role in the common project to advance knowledge and improve life experience. They ensure that the imperatives of science are balanced... read more →
The inaugural Tri-State Regional Meeting (co-hosted by NYSCF and the Doris Duke Charitable Foundation) was held in the NYSCF’s office January 31, 2018. With over 15 member organization represented, this... read more →
The cost of drug R&D makes up the bulk of the cost of prescription drugs because consumers not only pay for the medicines they are prescribed, but also for all... read more →
Under development by the Drug and Other Therapy Development working group, this “toolkit of toolkits” will enable member organizations to more easily identify and access existing and up-to-date resources relevant... read more →